

# **Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/MC9A194E7790EN.html>

Date: October 2022

Pages: 57

Price: US\$ 3,500.00 (Single User License)

ID: MC9A194E7790EN

## **Abstracts**

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 2 - Drugs In Development, 2022, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Schizophrenia, Depression, Treatment Resistant Depression, Anxiety Disorders, Drug Addiction, Major Depressive Disorder, Alzheimer's Disease, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Parkinson's Disease, Partial Seizure, Post-Traumatic Stress Disorder (PTSD), Psychosis and Unspecified Neurologic Disorders.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies

Involved in Therapeutics Development

Addex Therapeutics Ltd

Bristol-Myers Squibb Co

Camino Pharma LLC

Denovo Biopharma LLC

Eli Lilly and Co

Johnson & Johnson

Merck & Co Inc

Noema Pharma AG

Sumitomo Pharma Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles

BMT-133218 - Drug Profile

Product Description

Mechanism Of Action

DSP-3456 - Drug Profile

Product Description

Mechanism Of Action

JNJ-1813 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LY-3020371 - Drug Profile

Product Description

Mechanism Of Action

History of Events

mGlu2 NAM - Drug Profile

Product Description

Mechanism Of Action

History of Events

NOE-109 - Drug Profile

Product Description

Mechanism Of Action

History of Events

pomaglumed methionil - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBP-0069330 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SBP-9881 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile

Product Description

Mechanism Of Action

TS-134 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TS-161 - Drug Profile

Product Description

Mechanism Of Action

## History of Events

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones

Featured News & Press Releases

Nov 15, 2021: Addex strategic partner successfully completes Phase 1 in Japan with ADX71149

Aug 25, 2021: Camino Pharma initiates phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder

Jul 01, 2021: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

Jun 07, 2021: Addex starts phase 2 clinical study of ADX71149 for epilepsy

Jan 21, 2021: Addex ADX71149 receives IND approval to start a phase 2a clinical study in epilepsy

Sep 16, 2020: \$11.4 million NIH grant advances drug to treat nicotine addiction

Jun 30, 2020: Camino Pharma receives \$920K Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health

Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study

Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy

Sep 04, 2018: Addex's selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD

Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy

Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms

Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients

Appendix

Methodology

Coverage

Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Addex Therapeutics Ltd, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Camino Pharma LLC, 2022

Pipeline by Denovo Biopharma LLC, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Noema Pharma AG, 2022

Pipeline by Sumitomo Pharma Co Ltd, 2022

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

## I would like to order

Product name: Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/MC9A194E7790EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC9A194E7790EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970